Should You Buy the iShares Core S&P 500 ETF During the Stock Market Sell-Off? Here's What History Says.

The S&P 500 closed at 6,506 on March 20, down 7% from its all-time high; the seven largest tech names comprise 32.7% of the index and have fallen ~12% on average over the same period. The iShares Core S&P 500 ETF (IVV) tracks the index, has a 0.03% expense ratio, and the article argues history (10.6% CAGR since 1957; average 5% drawdown annually, 10% every ~2.5 years, 20% bear ~every 6 years) makes this a reasonable buying opportunity while advising scaled/ dollar-cost averaging given geopolitical risks in the Middle East and current volatility.

Analysis

The current pullback is creating a dynamic where market-cap weighting mechanically amplifies leadership concentration: any re-acceleration in flows into index products will disproportionately bid the largest AI/mega-cap names, while outflows bite hardest in the same names when sentiment flips. That feedback loop elevates liquidity and gamma risk in the Magnificent Seven; expect intraday realized vol to remain asymmetric and option skews to stay elevated for 1–3 months as dealers hedge delta.

Second-order winners if the market rotates away from concentration are cyclicals and cash-flow-heavy defensives. Industrials (CAT, GE, RTX) stand to gain from a modest re-pricing if recession fears recede and capex normalizes over the next 6–18 months, while healthcare cash generators (JNJ, ABBV) become preferred safe-yield replacements if geopolitical risk spikes and rates stabilize.

Key catalysts to watch are: 1) AI capex cadence (NVIDIA-led upgrades vs Intel inventory builds) over the next two earnings cycles; 2) a 10-year yield regime shift—if 10yr >4% quickly, growth multiples compress and financials (JPM, V) re-rate positively; 3) escalation in the Middle East triggering a 2–8 week tactical risk-off where utilities and large-cap defensives outperform. Any of these can reverse the current dispersion trade within weeks, but persistent AI revenue beat cycles would extend the concentration trade for 12+ months.

Key Decisions for Investors

• Long NVDA / Short INTC (pair): Buy NVDA Jan-2027 25% OTM LEAPS calls (allocate 2% portfolio notional) and short an equal dollar amount of INTC shares (or 3–6 month puts) to express asymmetric AI exposure relative to legacy silicon risk. R/R: if NVDA sustains AI-driven revenue growth, expect 3x+ on the calls; downside limited to premium (~2% notional) with short INTC providing partial funding but adds basis risk—horizon 12–18 months.
• Staged index exposure with tail hedge: Accumulate IVV via dollar-cost averaging over 3 months (weekly tranches) and buy a 3-month S&P 5% OTM put (~cost 0.5–1.0% of notional) each month to cap near-term drawdowns. R/R: preserves long-term beta upside (~+8–12% potential in 12 months) while limiting a concentrated 10–15% drawdown at acceptable hedging cost.
• Rotation pair into cyclicals: Long CAT and RTX (equal-weight, 1.5% portfolio each) vs short a concentrated mega-cap basket (AAPL, TSLA weighted to 1.5% total) for 6–12 months to play multiple compression/expansion. R/R: if cyclical recovery materializes this trade can deliver 20–40% on the long leg while the short offloads momentum risk; monitor PMI and CAPEX data monthly and cap max loss at 10% per leg.
• Defensive income overlay: Buy JNJ or ABBV (1–2% portfolio) and sell 3–6 month covered calls at 5–7% OTM to harvest volatility premium while retaining downside protection from dividends. R/R: generates 4–8% annualized carry in a sideways market and reduces drawdown in a short risk-off window; downside risk remains linked to sector-specific news—limit allocation to core defensive sleeve.